Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

A patient with advanced kidney cancer and no hepatitis C developed skin inflammation due to a drug called interferon alpha-2a.

Baricitinib is effective and safe for treating severe alopecia areata with ongoing use.

Lanadelumab greatly reduces hospital visits and angioedema episodes, improving life quality for hereditary angioedema patients.

Tofacitinib citrate improved nail dystrophy and pain in patients with alopecia universalis without causing side effects.

Tofacitinib significantly improved hair loss and lesions in a patient with overlapping autoimmune disorders.

A patient's hair loss may be linked to their diabetes medication, Sitagliptin.

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Infectious virus was not found after the third remdesivir dose, suggesting early end of isolation is possible.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.

Tofacitinib can cause a rare rash called SDRIFE, which resolves after stopping the drug.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.